



MAY 1 0 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

Dragan J. Karadzic  
The Dow Chemical Company  
Intellectual Property, B-1211  
2301 N. Brazosport Blvd.  
Freeport, Texas 77541

In re Application of  
MA et al.  
Application No.: 10/031,792  
PCT No.: PCT/US01/05927  
Int. Filing Date: 23 February 2001  
Priority Date: 25 February 2000  
Attorney Docket No.: 60364A  
For: ACTINIUM-225 COMPLEXES AND  
CONJUGATES FOR  
RADIOIMMUNOTHERAPY

DECISION ON PETITION  
UNDER 37 CFR 1.137(b)

The petition to revive under 37 CFR 1.137(b) filed 18 January 2002 in the above-captioned application is hereby **GRANTED** as follows:

Applicants' statement that "the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional" meets the requirements of 37 CFR 1.137(b)(3).

A review of the application file reveals that applicants have submitted the basic national fee of \$890 and the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

This application is being forwarded to the United States Designated/Elected Office (US/DO/EO) for continued processing including the issuance of a Notification of Missing Requirements (Form PCT/DO/EO/905) indicating that an oath or declaration is required.

Anthony Smith  
Attorney-Advisor  
PCT Legal Office  
Telephone: (703) 308-6314  
Facsimile: (703) 308-6459